HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Offner, H. Articles by Burrows, G. G. Search for Related Content PubMed PubMed Citation Articles by Offner, H. Articles by Burrows, G. G.

Treatment of Passive Experimental Autoimmune Encephalomyelitis in SJL Mice with a Recombinant TCR Ligand Induces IL-13 and Prevents Axonal Injury¹

Halina Offner^2,*,,, Sandhya Subramanian^*, Chunhe Wang, Michael Afentoulis^*, Arthur A. Vandenbark^*,,, Jianya Huan and Gregory G. Burrows^,¶

^* Neuroimmunology Research, Veterans Affairs Medical Center, Portland, OR 97239; Department of Neurology, Oregon Health & Science University, Portland, OR 97239; Department of Anesthesiology and Perioperative Medicine, Oregon Health & Science University, Portland, OR 97239; Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, OR 97239; and ^¶ Department of Biochemistry and Molecular Biology, Oregon Health & Science University, Portland, OR 97239

The major goal of this study was to evaluate the efficacy and mechanism of a rTCR ligand (RTL) construct (I-A^s/proteolipid protein (PLP)-139–151 peptide = RTL401) for treatment of SJL/J mice developing passive experimental autoimmune encephalomyelitis (EAE) that did not involve coimmunization with the highly inflammatory CFA. Our results demonstrated clearly that RTL401 was highly effective in treating passive EAE, with kinetics of recovery from disease very similar to treatment of actively induced EAE. The potent RTL401 treatment effect was reflected by a partial reduction of infiltrating mononuclear cells into CNS, minimal inflammatory lesions in spinal cord, and preservation of axons injured in vehicle-treated mice during the progression of EAE. Interestingly, in the absence of CFA, RTL401 treatment strongly enhanced production of the Th2 cytokine, IL-13, in spleen, blood, and spinal cord tissue, with variable effects on other Th1 and Th2 cytokines, and no significant effect on the Th3 cytokine, TGF-1, or on FoxP3 that is expressed by regulatory T cells. Moreover, pretreatment of PLP-139–151-specific T cells with RTL401 in vitro induced high levels of secreted IL-13, with lesser induction of other pro- and anti-inflammatory cytokines. Given the importance of IL-13 for protection against EAE, these data strongly implicate IL-13 as a dominant regulatory cytokine induced by RTL therapy. Pronounced IL-13 levels coupled with marked reduction in IL-6 levels secreted by PLP-specific T cells from blood after treatment of mice with RTL401 indicate that IL-13 and IL-6 may be useful markers for following effects of RTL therapy in future clinical trials in multiple sclerosis.

This article has been cited by other articles:

				S. Sinha, S. Subramanian, L. Miller, T. M. Proctor, C. Roberts, G. G. Burrows, A. A. Vandenbark, and H. Offner Cytokine Switch and Bystander Suppression of Autoimmune Responses to Multiple Antigens in Experimental Autoimmune Encephalomyelitis by a Single Recombinant T-Cell Receptor Ligand J. Neurosci., March 25, 2009; 29(12): 3816 - 3823. [Abstract] [Full Text] [PDF]

				J. Ochoa-Reparaz, A. Rynda, M. A. Ascon, X. Yang, I. Kochetkova, C. Riccardi, G. Callis, T. Trunkle, and D. W. Pascual IL-13 Production by Regulatory T Cells Protects against Experimental Autoimmune Encephalomyelitis Independently of Autoantigen J. Immunol., July 15, 2008; 181(2): 954 - 968. [Abstract] [Full Text] [PDF]

				D. L. Smith-Bouvier, A. A. Divekar, M. Sasidhar, S. Du, S. K. Tiwari-Woodruff, J. K. King, A. P. Arnold, R. R. Singh, and R. R. Voskuhl A role for sex chromosome complement in the female bias in autoimmune disease J. Exp. Med., May 12, 2008; 205(5): 1099 - 1108. [Abstract] [Full Text] [PDF]

				S. Sinha, L. J. Kaler, T. M. Proctor, C. Teuscher, A. A. Vandenbark, and H. Offner IL-13-Mediated Gender Difference in Susceptibility to Autoimmune Encephalomyelitis J. Immunol., February 15, 2008; 180(4): 2679 - 2685. [Abstract] [Full Text] [PDF]

				J. Huan, L. J. Kaler, J. L. Mooney, S. Subramanian, C. Hopke, A. A. Vandenbark, E. F. Rosloniec, G. G. Burrows, and H. Offner MHC Class II Derived Recombinant T Cell Receptor Ligands Protect DBA/1LacJ Mice from Collagen-Induced Arthritis J. Immunol., January 15, 2008; 180(2): 1249 - 1257. [Abstract] [Full Text] [PDF]

				S. Sinha, S. Subramanian, T. M. Proctor, L. J. Kaler, M. Grafe, R. Dahan, J. Huan, A. A. Vandenbark, G. G. Burrows, and H. Offner A Promising Therapeutic Approach for Multiple Sclerosis: Recombinant T-Cell Receptor Ligands Modulate Experimental Autoimmune Encephalomyelitis by Reducing Interleukin-17 Production and Inhibiting Migration of Encephalitogenic Cells into the CNS J. Neurosci., November 14, 2007; 27(46): 12531 - 12539. [Abstract] [Full Text] [PDF]

				G. Adamus, G. G. Burrows, A. A. Vandenbark, and H. Offner Treatment of Autoimmune Anterior Uveitis with Recombinant TCR Ligands. Invest. Ophthalmol. Vis. Sci., June 1, 2006; 47(6): 2555 - 2561. [Abstract] [Full Text] [PDF]